Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Crossing the Quality Chasm: A New Health System for the 21st Century.

Institute of Medicine (US) Committee on Quality of Health Care in America.

Washington (DC): National Academies Press (US); 2001.

2.

Effects of combination lipid therapy in type 2 diabetes mellitus.

ACCORD Study Group., Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP.

N Engl J Med. 2010 Apr 29;362(17):1563-74. doi: 10.1056/NEJMoa1001282. Erratum in: N Engl J Med. 2010 May 6;362(18):1748.

3.

PREVENTION OF ATHEROSCLEROSIS WITH LDL-C LOWERING - LIPOPROTEIN CHANGES AND INTERACTIONS: THE SANDS STUDY.

Howard WJ, Russell M, Fleg JL, Mete M, Ali T, Devereux RB, Galloway JM, Otvos JD, Ratner RE, Roman MJ, Silverman A, Umans JG, Weissman NJ, Wilson C, Howard BV.

J Clin Lipidol. 2009 Oct 1;3(5):322-331.

4.

Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trial.

Weir MR, Yeh F, Silverman A, Devereux RB, Galloway JM, Henderson JA, Howard WJ, Russell M, Wilson C, Ratner R, Sorkin J, Umans JG, Fleg JL, Stylianou M, Lee E, Howard BV.

J Clin Hypertens (Greenwich). 2009 Oct;11(10):540-8. doi: 10.1111/j.1751-7176.2009.00121.x.

5.

Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial.

Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA, Howard WJ, Lee ET, Mete M, Poolaw B, Ratner RE, Russell M, Silverman A, Stylianou M, Umans JG, Wang W, Weir MR, Weissman NJ, Wilson C, Yeh F, Zhu J.

JAMA. 2008 Apr 9;299(14):1678-89. doi: 10.1001/jama.299.14.1678.

6.

Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation.

Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL; American Diabetes Association.; American College of Cardiology Foundation..

Diabetes Care. 2008 Apr;31(4):811-22. doi: 10.2337/dc08-9018. Review. No abstract available.

PMID:
18375431
7.

Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes--the Stop Atherosclerosis in Native Diabetics Study (SANDS).

Russell M, Fleg JL, Galloway WJ, Henderson JA, Howard J, Lee ET, Poolaw B, Ratner RE, Roman MJ, Silverman A, Stylianou M, Weir MR, Wilson C, Yeh F, Zhu J, Howard BV.

Am Heart J. 2006 Nov;152(5):867-75.

PMID:
17070147
9.

AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute.

Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA; AHA/ACC.; National Heart, Lung, and Blood Institute..

Circulation. 2006 May 16;113(19):2363-72. No abstract available. Erratum in: Circulation. 2006 Jun 6;113(22):e847.

10.

Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors.

Howard BV, Best LG, Galloway JM, Howard WJ, Jones K, Lee ET, Ratner RE, Resnick HE, Devereux RB.

Diabetes Care. 2006 Feb;29(2):391-7.

PMID:
16443893
11.

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators..

Lancet. 2005 Nov 26;366(9500):1849-61. Erratum in: Lancet. 2006 Oct 21;368(9545):1415. Lancet. 2006 Oct 21;368(9545):1420.

PMID:
16310551
12.

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators..

Lancet. 2004 Aug 21-27;364(9435):685-96.

PMID:
15325833
13.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute.; American College of Cardiology Foundation.; American Heart Association..

Circulation. 2004 Jul 13;110(2):227-39. Review. Erratum in: Circulation. 2004 Aug 10;110(6):763.

14.

Hyperglycemia and microvascular and macrovascular disease in diabetes.

Klein R.

Diabetes Care. 1995 Feb;18(2):258-68. Review.

PMID:
7729308
15.

Mortality from coronary heart disease in the Tecumseh study. Long-term effect of diabetes mellitus, glucose tolerance and other risk factors.

Butler WJ, Ostrander LD Jr, Carman WJ, Lamphiear DE.

Am J Epidemiol. 1985 Apr;121(4):541-7.

PMID:
4014143
16.

Mortality among diabetics in a national sample.

Kleinman JC, Donahue RP, Harris MI, Finucane FF, Madans JH, Brock DB.

Am J Epidemiol. 1988 Aug;128(2):389-401.

PMID:
3394705
17.
Items per page

Supplemental Content

Support Center